Risks

Weak near-term liquidity versus larger pharma peers, with a current ratio of 0.26 and quick ratio of 0.08, can constrain working-capital flexibility and raise refinancing sensitivity.

Negative interest coverage and negative net debt to EBITDA indicate earnings are not covering financing costs, leaving CPHI more exposed than peers with positive operating leverage.

A 76.7-day cash conversion cycle, driven by 116.2 days of inventory, ties up cash longer than leaner specialty-drug peers and can pressure growth funding.

High inventory intensity versus peers increases the risk of obsolescence or discounting if demand softens, which can compress margins and reduce realized cash generation.

Opportunities

Low reported debt-to-equity of 0.10 and negative net debt to EBITDA suggest limited balance-sheet leverage, which can preserve optionality if operating performance improves versus more levered peers.

Longer inventory holdings can support service levels and product availability, potentially helping CPHI capture demand better than peers facing tighter stock positions.

If working-capital efficiency improves, the company could convert more sales into cash than peers with similarly thin liquidity, supporting reinvestment capacity.

The current capital structure leaves room for operational recovery to translate into outsized equity upside versus peers already carrying heavier debt burdens.

Overall Score

CPHI’s forward positioning is constrained by weak liquidity and poor interest coverage, while modest leverage and potential working-capital improvement provide only limited upside versus peers.